168 related articles for article (PubMed ID: 37409930)
1. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract][Full Text] [Related]
2. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Medicare Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity.
Pockros B; Shabet C; Stensland K; Herrel L
Urol Pract; 2023 Sep; 10(5):467-475. PubMed ID: 37347766
[TBL] [Abstract][Full Text] [Related]
4. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
6. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
Joyce DD; Sharma V; Jiang DH; Van Houten HK; Sangaralingham LR; Borah BJ; Kwon ED; Penson DF; Dusetzina SB; Tilburt JC; Boorjian SA
J Urol; 2022 Nov; 208(5):987-996. PubMed ID: 36094864
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
8. The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
Kazi DS; DeJong C; Chen R; Wadhera RK; Tseng CW
J Am Coll Cardiol; 2023 May; 81(21):2103-2111. PubMed ID: 37225364
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
10. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T; Jung J
J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
[TBL] [Abstract][Full Text] [Related]
13. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
17. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
20. Insulin Fills by Medicare Enrollees and Out-of-Pocket Caps Under the Inflation Reduction Act.
Myerson R; Qato DM; Goldman DP; Romley JA
JAMA; 2023 Aug; 330(7):660-662. PubMed ID: 37486673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
